# Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

> **NCT05835245** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Intrahepatic Cholangiocarcinoma

## Interventions

- **PROCEDURE:** Cryoablation
- **DRUG:** Sintilimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05835245
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-28
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835245, "Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05835245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*